Edition:
India

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

18.24USD
1:09am IST
Change (% chg)

$0.35 (+1.96%)
Prev Close
$17.89
Open
$17.89
Day's High
$18.51
Day's Low
$17.74
Volume
51,238
Avg. Vol
64,191
52-wk High
$24.85
52-wk Low
$11.74

Summary

Name Age Since Current Position

N. Anthony Coles

57 2015 Independent Chairman of the Board

Rodger Novak

49 2017 President, Co-Founder, Director

Samarth Kulkarni

38 President, Chief Business Officer

Kala Subramanian

49 2016 Senior Vice President - Strategic Development and Operations

Megan Wherry Menner

Senior Vice President of Human Resources

Sven Lundberg

53 2015 Chief Scientific Officer

Tony Ho

Head of Research and Development

Jim Kasinger

General Counsel, Secretary to the Board of Directors

Tyler Dylan-Hyde

55 2015 Chief Legal Officer

Jon Terrett

Head of Immuno-Oncology Research and Translation

Ali Behbahani

40 2015 Independent Director

Bradley Bolzon

56 2013 Independent Director

Pablo Cagnoni

54 2015 Independent Director

Simeon George

39 2015 Independent Director

Kurt von Emster

50 2015 Independent Director

Thomas Woiwode

45 2014 Independent Director

Chris Brinzey

Investor Relations Contact Officer

Biographies

Name Description

N. Anthony Coles

Dr. N. Anthony (Tony) Coles, Jr., M.D., has been Independent Chairman of the Board of CRISPR Therapeutics Ltd since October 2015. He is the founding investor and serves as Chairman and Chief Executive Officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Prior to founding Yumanity, he was Chairman and Chief Executive Officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. He has previously held various executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Merck & Co, Inc. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School. He earned his M.D. from Duke University, a master’s degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University. He currently serves as a member of the Board of Directors of McKesson Corporation, is Vice Chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. In March 2015, he was named to the NIH working group tasked with charting the course for President Obama’s Precision Medicine Initiative.

Rodger Novak

Dr. Rodger Novak, M.D., has been appointed as President, Co-Founder, Director of CRISPR Therapeutics Ltd., effective December 1, 2017. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. In his most recent position, he was Global Head, Anti-Infectives Research & Development at Sanofi, where he was responsible for small molecule and biologics R&D, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmaceutical career at Sandoz (Novartis), where he was appointed as the deputy Head of the Antibiotic Research Institute. He received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the United States in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Children’s Research Hospital and the Skirball Institute NYU Medical Center. During his academic career he authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. He is co-inventor of five patents.

Samarth Kulkarni

Dr. Samarth Kulkarni, Ph.D., has been appointed as Chief Executive Officer at CRISPR Therapeutics Ltd.. effective December 1, 2017. He has experience in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He was previously a Partner at McKinsey and Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice and served a number of biotechnology companies on topics ranging from strategy to operations. Additionally, he led initiatives in areas such as personalized medicine and immunotherapy, where he co-authored several publications. He received his Ph.D. in bioengineering and nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics, and published in numerous journals.

Kala Subramanian

Dr. Kala Subramanian, Ph.D., has been Senior Vice President - Strategic Development and Operations of CRISPR Therapeutics Ltd since June 2016. Prior to joining the Company, Dr. Subramanian served as Global Head of Strategic Development & Program Management in Oncology Development at Novartis Pharmaceutical Corporation, from December 2003 to June 2016. Prior to that, Dr. Subramanian served as Senior Project Manager at Millennium Pharmaceuticals, from May 2001 to December 2003. Dr. Subramanian also served as Senior Consultant at Accenture Consulting, from May 1998 to April 2001. Dr. Subramanian received a Ph.D. in Chemistry from Cornell University and a M.Sc. in Chemistry from Indian Institute of Technology, Madras (India). She completed post-doctoral work at Duke University Medical Center.

Megan Wherry Menner

Ms. Megan Wherry Menner serves as Senior Vice President of Human Resources at CRISPR Therapeutics Ltd. She was previously with Merck KGaA for eight years, most recently as Vice President and Head of HR for the global Merck Millipore Life Science business. In this role, she was responsible for HR strategy, business partnership and all HR functions aligned to the Life Science business, including the people and organization integration of the Sigma-Aldrich acquisition. Also at Merck KGaA, she served as VP and Head of HR International where she had responsibility for all HR team members in 60+ countries as well as VP and Head of HR for EMD Serono, where she led all HR functions for the US Pharma business. Before that, she spent five years at Novartis through a period of rapid growth, most recently serving as Head of Talent and Culture Development for the entire Research organization globally, and held several senior HR business partner roles in the US and in the UK. She also worked in Leadership Development at Amgen and HR Business Partnership at Bristol-Myers Squibb and earlier in her career in Talent Acquisition at a software start-up company as an outgrowth of MIT Sloan Business School that was acquired by Lucent Technologies. She earned both her Bachelor’s degree in Psychology and Economics and her Master’s degree in Human Resources and Organizational Behavior from Cornell University.

Sven Lundberg

Dr. Sven Ante (Bill) Lundberg, M.D., has been Chief Scientific Officer of CRISPR Therapeutics Ltd since February 2015. Prior to that, he was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc., or Alexion, a biopharmaceutical company, from March 2011 to January 2015. From March 2010 to January 2011, he was Chief Medical Officer at Taligen Therapeutics, Inc., a biotechnology company that was acquired by Alexion in January 2011, and Vice President of Clinical Development at Antisoma Plc, or Antisoma, from May 2008 to March 2010. he also served as Vice President of Clinical Development at Xanthus Pharmaceuticals, Inc. from 2004 until it was acquired by Antisoma in 2008. Previous to that, he served as the Medical Director at Wyeth (acquired by Pfizer Inc. in January 2009) and Medical Director at Genzyme Corporation. He received an M.D. from Stanford University School of Medicine, an MBA from the Isenberg School of Management at the University of Massachusetts – Amherst, and a B.S. in Biology from the Massachusetts Institute of Technology, or MIT. He completed post-doctoral work at the Whitehead Institute for Biomedical Research at MIT.

Tony Ho

Dr. Tony Ho serves as Head of Research and Development at CRISPR Therapeutics Ltd. He was previously Senior Vice President and Head of Oncology Integration and Innovation at AstraZeneca. During his tenure at AstraZeneca, he oversaw both development and commercialization of the two key drugs – Lynparza, a first-in-class PARP inhibitor for ovarian cancer and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug for bladder cancer. For both drugs, he led the program through filing, regulatory defense, payer access, and commercial launch, and initiated Phase III development across multiple tumor types. Prior to joining AstraZeneca, he was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Dr. Ho was the Co-Founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company. He completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine. After an internship in Internal Medicine at the Massachusetts General Hospital, Tony completed his residency and neurophysiology fellowship in the Department of Neurology at the Johns Hopkins Hospital. He was Assistant Professor at Johns Hopkins Hospital in the areas of neuropathy and neuromuscular diseases. He has published widely in several fields with over 80 papers and is co-inventor of seven patents. He is currently adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.

Jim Kasinger

Mr. Jim Kasinger serves as General Counsel and Secretary to the Board of Directors at CRISPR Therapeutics Ltd. He has nearly 20 years of experience advising and counseling private and public companies in the biotechnology and technology sectors. Prior to joining the Company, he was the General Counsel and Secretary of Moderna Therapeutics, a Cambridge-based biotechnology company, where, among other things, he helped lead two equity financings and several collaborations including with AZ, Merck and Vertex. Before that, he was the General Counsel at PlumChoice, Inc., a provider of technical support services to Fortune 1000 companies. Before going in-house, he was a partner in the Business Practice Group at the global law firm, Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies in all stages of their life cycles, from formation, to obtaining seed and growth financings, to initial public offering, merger or sale. He started his legal career as an associate at Testa, Hurwitz & Thibeault. He received his J.D. from Boston College Law School, graduating cum laude, and a B.A. from Wheaton College, graduating magna cum laude.

Tyler Dylan-Hyde

Dr. Tyler M. Dylan-Hyde, J.D., Ph.D., has been Chief Legal Officer of CRISPR Therapeutics Ltd since January 2015. Prior to joining the Company, he was the Chief Business Officer and General Counsel of Taxus Cardium Partners Group (formerly Cardium Therapeutics, Inc.), from October 2005 to December 2014, and has served as a member of the board of directors since October 2005. Dr. Dylan-Hyde also served as the Chief Business Officer and General Counsel, and a member of the Board of Directors of Tissue Repair Company from August 2006 to November 2014. Prior to that, he was Vice President and General Counsel at Collateral Therapeutics, Inc. (acquired by Schering AG (now Bayer Healthcare Pharmaceuticals) in March 2002), Chief Business Officer and General Counsel at InnerCool Therapies Inc. (acquired by Royal Philips (now ZOLL Medical Corporation) in July 2009), and a Partner at Morrison & Foerster LLP, where he specialized in intellectual property, licensing and corporate transactions. He received a J.D. from the University of California, Berkeley, School of Law, a Ph.D. in Biology from the University of California, San Diego, and a B.Sc. in Cell, Molecular and Developmental Biology from McGill University.

Jon Terrett

Dr. Jon Terrett, Ph.D., serves as Head of Immuno-Oncology Research and Translation at CRISPR Therapeutics Ltd. Prior to joining CRISPR Therapeutics, he was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, he has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. He received a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.

Ali Behbahani

Dr. Ali Behbahani, M.D., has been Independent Director of CRISPR Therapeutics Ltd since April 2015. He joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. He concurrently earned his M.D. degree from the University of Pennsylvania School of Medicine and his MBA degree from the University of Pennsylvania Wharton School, where he graduated with honors and was a Palmer Scholar. He graduated Summa Cum Laude and received his B.S.E., B.M.E. and E.E. degrees with distinction in biomedical engineering, electrical engineering and chemistry from Duke University.

Bradley Bolzon

Dr. Bradley J. (Brad) Bolzon, Ph.D., has been Independent Director of CRISPR Therapeutics Ltd since November 2013. He has more than 13 years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing, with a particular emphasis on new company start-ups. Prior to joining Versant, he served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, he held executive roles at Lilly in drug discovery, clinical research, regulatory affairs and business development. He received his Ph.D. and an M.S. in pharmacology from the University of Toronto. He conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada.

Pablo Cagnoni

Dr. Pablo J. Cagnoni, M.D., has been Independent Director of CRISPR Therapeutics Ltd since December 2015. He is currently the President and CEO of Tizona Therapeutics and Managing Director of MPM Capital. Most recently, he served as President of Onyx Pharmaceuticals where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics, and prior to that Chief Medical Officer of OSIPharmaceuticals. Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from the University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni is currently on the board of directors of Harpoon Therapeutics and he is Executive Chairman of Blade Therapeutics, both private biotechnology companies.

Simeon George

Dr. Simeon J. George, M.D., has been Independent Director of CRISPR Therapeutics Ltd since April 2015. He joined SR One in 2007 and leads SR One’s investment activities on the West Coast. Prior to joining SR One, he was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. He received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. He received his M.D. from the University of Pennsylvania School of Medicine and his MBA (Mayer Scholar) from the University of Pennsylvania Wharton School.

Kurt von Emster

Mr. Kurt H. von Emster has been Independent Director at CRISPR Therapeutics Ltd since April 2015. He currently serves as Managing Partner at Abingworth LLP, where he has been employed as a Partner since January 2015. He also has served as a member of the board of directors of SutroVax, a biopharmaceutical vaccine company, since July 2015 where he is currently Chairman, and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr. von Emster previously served on the board of directors of the following companies: Kesios Therapeutics, a biotherapeutics company, from November 2015 to December 2016, Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015, Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010, and Somaxon Pharmaceuticals (acquired by Pernix Therapeutics in March 2013) from September 2005 to January 2013. In addition, he co-founded venBio LLC, a health-care focused investment firm, in 2009, and served as Partner until 2014. Prior to that, he was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2001 to 2009. He was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. He received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst, or CFA.

Thomas Woiwode

Dr. Thomas F. (Tom) Woiwode, Ph.D., has been Independent Director of CRISPR Therapeutics Ltd since April 2014. He has been with Versant Ventures since 2002, serving as a Venture Partner since 2008 and a Managing Director since 2014. He has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for infectious diseases. He led the process that culminated in the sale of Okairos to GlaxoSmithKline. Prior to his role with Okairos, he co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb). Prior to his role as a Venture Partner, he was a Principal at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. He was a research scientist at XenoPort before joining Versant. He currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone, Therachon and Kanyos Bio. He earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Chris Brinzey